Genprex, Inc. 8-K

What Happened
Genprex, Inc. (GNPX) issued a press release on May 14, 2026 disclosing that research collaborators presented positive preclinical data for the company’s diabetes gene therapy candidate (Pdx1/MafA, also called PM or GPX-002) at the ASGCT Annual Meeting on May 13, 2026 in Boston. In a mouse study, retrograde pancreatic delivery of an AAV‑8 vector encoding Pdx1 and MafA (under either a CMV promoter for broad islet targeting or a rat insulin promoter for β‑cell specific targeting) produced major improvements in diabetes control by four weeks. Key readouts included intraperitoneal glucose tolerance testing, insulin tolerance testing, ex‑vivo glucose‑stimulated insulin secretion (GSIS), electron microscopy and single‑cell RNA sequencing; treated high‑fat diet (HFD) mice showed restored insulin secretion, reversal of hyperglycemia, increased mature insulin granules and a transcriptomic shift toward more mature β‑cells. The company noted the delivery approach is technically translatable to humans via endoscopic retrograde cholangiopancreatography (ERCP).

Key Details

• Filed May 14, 2026 (press release); data presented May 13, 2026 at the ASGCT Annual Meeting in Boston.
• Gene therapy candidate: Pdx1/MafA (PM, GPX-002) delivered by AAV‑8; promoters tested: CMV (global islet targeting) and RIP (β‑cell specific).
• In HFD mice, CMV‑PM treated islets had ex‑vivo GSIS similar to regular‑diet mice and higher than HFD controls; RIP‑PM treatment reversed hyperglycemia by four weeks.
• Additional findings: increased total and mature insulin granules on EM and a shift in β‑cell transcriptomic “pseudotime” toward maturity after PM treatment.

Why It Matters
This is preclinical data indicating GPX‑002 may directly improve β‑cell function and maturation, addressing a core defect in Type 2 diabetes rather than just symptoms. For investors, the results could support Genprex’s R&D narrative and pipeline value, but they are early-stage (animal) findings — not clinical proof of safety or efficacy in humans. The 8‑K includes the company’s cautionary forward‑looking language noting substantial risks and uncertainties (including clinical development, regulatory approval, manufacturing, financing and Nasdaq listing risks). Investors should view these results as encouraging preclinical progress but dependent on future clinical development and regulatory milestones.